Novartis AG
OTC:NVSEF

Watchlist Manager
Novartis AG Logo
Novartis AG
OTC:NVSEF
Watchlist
Price: 152 USD -1.84% Market Closed
Market Cap: $312.5B

Relative Value

The Relative Value of one NVSEF stock under the Base Case scenario is hidden USD. Compared to the current market price of 152 USD, Novartis AG is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NVSEF Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

NVSEF Competitors Multiples
Novartis AG Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CH
Novartis AG
OTC:NVSEF
219B USD 5 19.3 15.5 20
US
Eli Lilly and Co
NYSE:LLY
954.9B USD 16.1 51.8 34.8 37.3
US
Johnson & Johnson
NYSE:JNJ
546.2B USD 5.8 20.4 14.2 17.4
CH
Roche Holding AG
SIX:ROG
268.4B CHF 4.4 28.6 12.2 14.2
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP 4.9 30.3 19.7 28.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.3 11.4 13.2
US
Merck & Co Inc
NYSE:MRK
265.4B USD 4.1 13.9 9.9 11.7
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
147.6B USD 2.3 15 7.6 10.4
FR
Sanofi SA
PAR:SAN
94.4B EUR 1.4 6.9 6.3 6.3
US
Bristol-Myers Squibb Co
NYSE:BMY
111.6B USD 2.3 18.5 6.7 8.7
P/E Multiple
Earnings Growth PEG
CH
Novartis AG
OTC:NVSEF
Average P/E: 22.1
19.3
17%
1.1
US
Eli Lilly and Co
NYSE:LLY
51.8
54%
1
US
Johnson & Johnson
NYSE:JNJ
20.4
6%
3.4
CH
Roche Holding AG
SIX:ROG
28.6
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.3
38%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
16.3
2%
8.2
US
Merck & Co Inc
NYSE:MRK
13.9
14%
1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15
27%
0.6
FR
Sanofi SA
PAR:SAN
6.9
25%
0.3
US
Bristol-Myers Squibb Co
NYSE:BMY
18.5
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CH
Novartis AG
OTC:NVSEF
Average EV/EBITDA: 43.9
15.5
6%
2.6
US
Eli Lilly and Co
NYSE:LLY
34.8
34%
1
US
Johnson & Johnson
NYSE:JNJ
14.2
2%
7.1
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
19.7
10%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
1%
11.4
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
FR
Sanofi SA
PAR:SAN
6.3
8%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
6.7
-9%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CH
Novartis AG
OTC:NVSEF
Average EV/EBIT: 93.9
20
12%
1.7
US
Eli Lilly and Co
NYSE:LLY
37.3
37%
1
US
Johnson & Johnson
NYSE:JNJ
17.4
6%
2.9
CH
Roche Holding AG
SIX:ROG
14.2
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
28.9
23%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
0%
N/A
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
7%
1.5
FR
Sanofi SA
PAR:SAN
6.3
15%
0.4
US
Bristol-Myers Squibb Co
NYSE:BMY
8.7
10%
0.9